Case: A 28-Year-Old Man. When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis.

Slides:

Advertisements

Similar presentations

Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.

Advertisements

“Antibiotics and corticosteroids: Indications and approaches”

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.

Cumulative Probability of Developing Colon Cancer in UC Patients

Symptom Control and Enhancing Functioning in Schizophrenia

Novel Agents in Multiple Myeloma The Pharmacist's View on Therapy

PrEP: A Case-by-Case Approach

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Goals of Therapy for Patients With UC

Optimizing Use of Biological Agents in Ulcerative Colitis

Thrombosis, Cancer, and NOACs

Glaucoma Progression.

The Changing Therapeutic Landscape of CINV

UNDERSTANDING RISK STRATIFICATION IN PAH:

Ask the Onychomycosis Expert, Part 2

Unmet Needs in the Secondary Prevention in ACS

Improving Acne Outcomes

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

Before and After: Patient Cases in Onychomycosis

Complicated Cases in Ulcerative Colitis

Therapeutic Strategies in the Management of Mild-to-Moderate Atopic Dermatitis.

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Pathways in Managing Ulcerative Colitis

Optimizing Management of Advanced Bladder Cancer

Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy

Best Practices in Metastatic Colorectal Cancer

VTE Treatment Conventional Approach

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

From Symptom Management to Communication in Advanced GI Cancers

Patient Case: KC. Optimizing Treatment of Mild to Moderate Ulcerative Colitis: A Case-Based Perspective.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Antithrombotic Protection in CAD and HF

Managing Adverse Events With New Oral Therapies in CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Charting Progress in MS Treatment:

Illustrations in Ulcerative Colitis

Personalized Therapy in Relapsed or Refractory CLL

Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.

Advancing the Treatment of IBD With Biologics

Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma

The Evolving Treatment Landscape in Atopic Dermatitis

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?

Prolonging the Effects of Factor IX Replacement Therapy in Hemophilia B.

Cancer-Associated Thrombosis

CAD and HF Often Coexist

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study William J. Sandborn, William F. Stenson,

Proteasome Inhibitors and Patients

Communicating With Your Patients About Major Depressive Disorder

Incorporating Prostacyclins Into Practice

Improving Adherence to Antiplatelet Therapy After an ACS Event

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Program Goal. Program Goal Disclaimer Overview.

Oral Therapies in MS.

Prostacyclin Pathway Agents in Action

AMD Therapy: Where Are We Now and Where Are We Going?

VKA Reversal and LVADs.

Tailoring Therapy in the Newly Diagnosed Patient With CLL

PAH Pathways: What Do the Data Tell Us?”

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Comparative Studies of Biologics in Ulcerative Colitis

Presentation transcript:

When a 5-ASA Agent No Longer Maintains Remission in a Patient With Ulcerative Colitis

Case: A 28-Year-Old Man

Case (cont)

Sequential Therapies for UC

Case: Next Steps

Case: Next Steps

Treatment of Panulcerative Colitis That Is Unresponsive to Oral Mesalamine 2.4 g/d

Treatment of Panulcerative Colitis That Is Unresponsive to Oral Mesalamine 2.4 g/d (cont)

Treatment of Panulcerative Colitis That Is Unresponsive to Oral Mesalamine 2.4 g/d (cont)

Efficacy and Safety of Budesonide MMX

Budesonide MMX After Treatment With 5-ASA

Case: Conclusion

Options for Maintaining Remission

Patient Adherence

Adherence Is Dependent on Multiple Factors

Summary

Abbreviations

References

References (cont)